Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 13,118 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05064280RecruitingPhase 2
Pembrolizumab plus lenvatinib for brain metastases from solid tumors
This Phase 2 trial studies whether combining pembrolizumab with lenvatinib can shrink or control brain metastases in people with triple-negative breast cancer, lung cancer, or other solid tumors. It focuses on patients who have measurable brain lesions that can be followed on MRI.
Houston, TexasAges 18 years+ - NCT05066139Recruiting
Study of older adults with digestive cancer
This study checks how well different care plans work for people age 75 and older who have digestive cancer and are about to start chemotherapy or targeted therapy. The goal is to improve treatment support and outcomes by doing a detailed, multidisciplinary evaluation.
StrasbourgAges 75 years+ - NCT05068310Recruiting
Test a high-detail eye-like scan on skin tumors before biopsy
This study tests a high-resolution scan (called OCT) to better see skin tumors before they’re removed or biopsied. It may help doctors evaluate both non-pigmented and pigmented skin spots that look like possible skin cancer.
BerlinAges 18 years+ - NCT05076500Recruiting
How radiotherapy changes a tumor’s immune response
This study looks at how a tumor’s immune system responds when you receive radiotherapy. It involves taking a planned pre-treatment biopsy so researchers can study immune and tumor changes and see if radiotherapy affects them.
ManchesterAges 18 years+ - NCT05078671RecruitingPhase 4
Testing a drug-boost to improve olaparib levels and side effects
This Phase 4 study tests whether adding a “booster” medicine can raise olaparib levels in the body so it may be better tolerated and more cost-effective. You may be eligible if you are already taking olaparib and meet health and medication safety requirements.
's-HertogenboschAges 18 years+ - NCT05083754RecruitingPhase 1
New glioblastoma trial testing immune drug plus radiation
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
Baltimore, MarylandAges 18–100 - NCT05082961Recruiting
Blood immune markers and brain radiation after head/neck surgery
This study looks at immune system signals in your blood during and after postoperative radiation therapy for certain head and neck cancers involving the brain or skull base. Researchers want to see whether these “immune markers” relate to treatment response or side effects.
CaenAges 18 years+ - NCT05088187Recruiting
Study of thinking and quality of life after thyroid surgery
This study looks at how thyroid surgery affects thinking (cognition) and day-to-day quality of life. It may help patients and doctors understand what to expect and how to support people after surgery.
StockholmAges 18 years+ - NCT05088395Recruiting
Blood tests to track cancer signals after treatment
This study measures “circulating tumor markers,” meaning substances from cancer that can show up in blood, to better understand how cancer is doing after treatment. You may join if you recently received cancer care at a participating center and meet basic study and follow-up requirements.
ParisAges 18 years+ - NCT05091372RecruitingPhase 2
Maintenance treatment after transplant for newly diagnosed myeloma
This trial tests whether using belantamab mafodotin plus lenalidomide as long-term maintenance after an autologous stem cell transplant can keep multiple myeloma under control, guided by minimal residual disease (MRD). MRD is a very small amount of disease that may remain after transplant, and the study helps see if treating those patients better improves outcomes.
Houston, TexasAges 18 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05097820Recruiting
Study of silicone gel testicular implants after placement
This is an observational study that follows people who receive silicone gel-filled testicular implants. It aims to collect real-world information about safety and healing to help improve future care.
Ghent, East-FlandersAges birth–110 years - NCT05097625Recruiting
Testing early detection of head and neck cancer relapse
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
LondonAges 18 years+ - NCT05099809Recruiting
Hyperthermia plus treatment for locally advanced cancers
This registry study looks at whether adding hyperthermia (raising body temperature) is safe and effective for people with certain locally advanced, non-spread cancers. It will follow outcomes to help doctors understand who may benefit and what side effects to expect.
Sevāgrām, MaharashtraAges 18 years+ - NCT05100095RecruitingPhase 2
Radiation schedule study for Merkel cell skin cancer
This Phase 2 trial tests a specific radiation timing/dose schedule for Merkel cell carcinoma (MCC), a rare and aggressive skin cancer. It may help by improving control of the cancer after surgery, especially in higher-risk cases (like lymph nodes).
Houston, TexasAges 18 years+ - NCT05100342Recruiting
Testing a points score to predict 30-day survival
This study checks whether a prediction “points score” can estimate the chance of being alive 30 days after a person is referred for comfort-focused radiation therapy. It may help doctors choose the most helpful next steps and better plan follow-up care.
Avon, IndianaAges 18 years+ - NCT05106296RecruitingPhase 1
Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Augusta, GeorgiaAges 3–25 - NCT05108090Recruiting
Sentinel node biopsy for head and neck skin cancer
This study checks whether a “sentinel lymph node biopsy” can help find if skin cancer in the head or neck has spread to nearby lymph nodes. It uses special dye/medicine and imaging, then removes the cancer and the sentinel node soon after scanning.
Indianapolis, IndianaAges 18 years+ - NCT05112614Recruiting
Study links gut bacteria to cancer treatment response
This study looks at how the bacteria in your gut change during cancer treatment (and during some blood stem cell transplants). It may help researchers understand why some people respond differently and guide better future treatment.
Scottsdale, ArizonaAges 18–99 - NCT05117723Recruiting
IPMN cyst database to help predict pancreatic cancer risk
This study collects information from people who have an IPMN cyst in the pancreas to help predict who may be at higher risk of pancreatic cancer. It may help your care team estimate risk and plan follow-up more effectively.
Fitzroy, VictoriaAges 18–90 - NCT05119244Recruiting
Study of environment factors in lung cancer
This study looks at how environmental factors may relate to lung cancer in adults. If you are between 18 and 59 and were treated for primary lung cancer at a participating hospital, you may be able to join.
Le Plessis-RobinsonAges 18–59 - NCT05120518Recruiting
Donate a child’s tumor tissue for research after passing
This study collects a child’s tumor tissue and cells after death to help researchers learn more about cancers and other tumor conditions. You can take part if the required consent and permission are completed.
Chicago, IllinoisAges Any age - NCT05122806Recruiting
Study of cancer biology in ALK-positive advanced lung cancer
This study looks at biological changes in advanced lung cancer that has an ALK rearrangement, using regular blood samples (and sometimes tumor tissue if available). It may help researchers better understand how this cancer behaves and how it responds to first-line ALK-targeted treatment.
Saint-Denis, La RéunionAges 18 years+ - NCT05123625Recruiting
Testing lymph node removal during bladder cancer surgery
This study looks at whether removing nearby lymph nodes during radical cystectomy (bladder removal) improves outcomes for people with high-risk non–muscle-invasive bladder cancer. It may help doctors choose the best surgical approach to reduce the chance of cancer coming back.
Nanjing, JiangsuAges 18–75
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 13,118 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.